Active ingredients: cinnarizine; dimenhydrinate;
1 tablet contains cinnarizine 20 mg and dimenhydrinate 40 mg;
Excipients: microcrystalline cellulose, corn starch, talc, hypromellose, colloidal silicon dioxide, magnesium stearate, croscarmellose sodium.
Adults. 1 tablet 3 times a day after meals, without chewing, with a small amount of liquid.
Elderly patients. Dose adjustment is not required.
The duration of the preparation should not exceed 4 weeks. The decision on longer treatment should be made by the doctor.
pregnant
Should not be used during pregnancy.
Children
Children use the preparation Arlevert® is not recommended due to the lack of data on its use.
Drivers
The preparation Arlevert® can cause drowsiness, impaired coordination of movements, dizziness, an increase in reaction time, especially at the initial stage of treatment. In such cases, patients should not drive vehicles or other mechanisms.
Symptoms of an overdose of Arlevert include drowsiness, dizziness and ataxia, in combination with such manifestations of anticholinergic action as dry mouth, redness of the face, dilated pupils, tachycardia, fever, headache and urinary retention. Complications such as convulsions, hallucinations, agitation, respiratory depression, arterial hypertension, tremor and coma may also occur (especially in case of severe overdose).
Treatment. In case of respiratory depression or acute circulatory failure, the patient should be given supportive therapy. It is recommended to wash the stomach with saline sodium chloride solution. Body temperature should be closely monitored, since intoxication with antihistamines can lead to fever (especially in children).
The most commonly reported adverse reactions in clinical trials were confusion (including drowsiness, tiredness, fatigue, drowsiness) in 8% of patients in clinical trials, and dry mouth in 5% of patients. participating in clinical trials. Usually these reactions are mild and disappear within a few days, even with prolonged use.
No preparation interaction studies have been conducted.
The anticholinergic efficacy of Arlevert® may be enhanced by the use of MAO inhibitors; in some cases, paralytic syndrome (sometimes life-threatening), urinary retention, increased intraocular pressure, a decrease in blood pressure, a sedative effect on the central nervous system and respiratory disorders have also been reported.
Special storage conditions are not required.
Keep out of the reach of children.
Shelf life - 3 years.
There are no reviews for this product.